SIL-TAL1融合基因阳性急性T淋巴细胞白血病19例临床分析

OBJECTIVE: To assess the clinical characteristics and prognosis of patients with SIL-TAL1-positive T-cell acute lymphoblastic leukemia（T-ALL）. METHODS: The clinical data of 19 SIL-TAL1-positive T-ALL patients admitted to the First Affiliated Hospital of Soochow University between January 2014 and February 2022 were retrospectively computed and contrasted with SIL-TAL1-negative T-ALL patients. RESULTS: The median age of the 19 SIL-TAL1-positive T-ALL patients was 15（7 to 41 years）, including 16 males（84.2％）. SIL-TAL1-positive T-ALL patients had younger age, higher WBC, and hemoglobin compared with SIL-TAL1-negative T-ALL patients. There was no discrepancy in gender distribution, PLT, chromosome abnormality distribution, immunophenotyping, and complete remission（CR）rate. The 3-year overall survival（OS）was 60.9％ and 74.4％, respectively（HR＝2.070, P＝0.071）. The 3-year relapse-free survival（RFS）was 49.2％ and 70.6％, respectively（HR＝2.275, P＝0.040）. The 3-year RFS rate of SIL-TAL1-positive T-ALL patients was considerably lower than SIL-TAL1-negative T-ALL patients. CONCLUSION: SIL-TAL1-positive T-ALL patients were connected to younger age, higher WBC, higher HGB, and poor outcome.